COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
- PMID: 34848425
- PMCID: PMC8634247
- DOI: 10.1136/bcr-2021-246700
COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
Abstract
A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.
Keywords: COVID-19; medical management.
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
References
-
- National Institutes of Health . COVID-19 treatment guidelines, 2021. Available: https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/ [Accessed 1 Sep 2021]. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical